Vetter Pharma-Fertigung GmbH & Co. KG

Our Chemistry, Manufacturing and Controls (CMC) specialists help customers manage the product's compliance at every step, from clinical development to market authorization. With decades of experience, our experts provide support in navigating regulatory milestones, including site registration, product regi...

Our Vetter Development Services help biopharma customers lay a foundation of scalability, quality, and sustainable value for drug product profiles. We support drug developers in navigating key steps, decisions, and transitions in the product development cycle. This includes primary packaging evaluation, pr...

For over 40 years, our fill and finish services have helped to keep the world supplied with injectable therapies, many of which are lifesaving. Our partnerships with customers start in the first steps of clinical manufacturing through commercial-scale filling and beyond, including management throughout the...

The injectable drug market is rapidly evolving and includes an array of delivery devices from autoinjectors to pens and other intuitive formats. We provide partnership for drug owners driven by the top-quality, complex considerations and flexibility expected. These services include assembly process des...

From a drug product’s first raw materials to its release-ready batches, our experts rigorously evaluate and verify a product’s quality at key steps throughout the manufacturing process. Analytical services include material testing to verify product quality from the early stages of development, cGMP-com...

We place heightened focus on your success as your strategic partner.

We produce aseptically prefilled syringes, cartridges, vials and dual-chamber systems as a globally operating CDMO partner. We are a family-owned, independent company rooted in 70+ years of history. We do not manufactu...

V-OVS® next is a new evolution of the V-OVS® Luer Lock closure system: A product that has helped shape the market for 20+ years. Several innovative updates further enhance the system’s functionality, including an optimized opening mechanism and a streamlined design that fits an even wider range of syri...

The latest in our series for the CPHI Podcast Series focuses on partnerships, specifically those between pharma companies and CDMOs. Expert Christine Fürst from Vetter comments on how to make successful and lasting partnerships in the industry. 

For over four decades, pharma and biotech companies around the world have relied on us to put their parenteral medications on a path to success. We’re proud to help our customers advance their valuable products with innovative services, cutting-edge technology, and flexible, robust, scalable processes that set our partnership apart.

Vetter (Ravensbury, Germany), the aseptic filling and packaging CDMO has signed up to the UN Global Compact Network. 

From your first product batches to phase 3 scale-up, we provide the comprehensive fill and finish services you need at every step in the development of your injectable drug candidate. Explore the flexible, high-quality, technically advanced support we provide from our dedicated clinical manufacturing sites in the US and EU.

Opportunities for contract development and manufacturing organisations (CDMOs) in China continue to grow but many questions remain over what the future of the sector will look like in the world's second largest pharmaceutical market.

We at Vetter provide expert device assembly and packaging services for injectable drug products, including autoinjectors and pens. Our processes are optimized to suit the specific needs of each product by taking into account primary packaging, product characteristics, and secondary packaging plans. Additionally, we offer a versatile range of devices and components, including patient-centric delivery formats and components that ensure the usability and integrity of syringe-based products.

Looking for world-class aseptic fill finish manufacturing services? Look no further. With over 40 years of experience, we specialize in high-quality cGMP aseptic filling for injectable drug products. From clinical manufacturing to commercial-scale filling and beyond, we're here to help you succeed at every stage of your product's life cycle. Our dedicated teams and flexible services are prepared to meet timelines and milestones to bring vital medications to patients around the globe.

This presentation shares key lessons learned from the ongoing journey of preparing Vetter’s V-OVS® next syringe closure system for market readiness. Based on practical experience gathered throughout the development and pre-commercial phases, it highlights insights into navigating regulatory pathways, aligning cross-functional teams, and managing complexity in combination product development. The session discusses challenges encountered, strategies applied, and critical factors that have shaped the project’s direction so far.

In today’s rapidly evolving global landscape, the (bio-)pharmaceutical industry faces increasing complexity, from shifting market dynamics to rising sustainability expectations. The keynote explores how long-term, trust-based relationships between Contract Development and Manufacturing Organizations (CDMOs) and their customers can unlock greater innovation, resilience, and value in the development and manufacturing of complex injectable therapies. Drawing from real-world insights and industry experience, the session highlights how forward-looking collaboration, shared goals, and proactive adaptation are the key drivers of continuous change. It also addresses the growing role of quality and sustainability as crucial factors in strategic decision-making. Attendees will gain inspiration and practical perspectives on how to shape the future of injectables through long-term cooperation.

This presentation looks at the crucial role of syringe closure systems in the field of prefilled syringes and injection devices, offering scientific insights into container closure development. With extensive experience of legacy closure systems, our company explores the potential of integrating historical knowledge with contemporary development methods to create a novel closure system. This presentation will showcase how efficient development strategies and state-of-the-art methods can be used to create a development program that is based on history, is driven by innovation and adheres to the latest combination product regulations.